[CAS NO. 6384-92-5] NMDA
PRODUCTS SPECIFICATIONS [6384-92-5]
DESCRIPTION [6384-92-5]
Overview
| MDL | MFCD00004226 |
|---|---|
| Molecular Weight | 147.13 |
| Molecular Formula | C5H9NO4 |
| SMILES | O=C(O)C[C@H](C(O)=O)NC |
5 Publications Citing Use of MCE
Summary
NMDA is a specific agonist for NMDA receptor mimicking the action of glutamate, the neurotransmitter which normally acts at that receptor.
IC50 & Target
|
Human Endogenous Metabolite |
NMDA Receptor |
In Vitro
NMDA exerts a significant augmentation of the adrenal binding independently of the incubation temperature in a concentration-dependent manner [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
NMDA (0.2 nM) shows significant effects on MF, IF, IL, and EL, respectively, decreasing the mount and intromission frequencies, and shortening the intromission and ejaculation latencies. NMDA and AP-5 significantly, respectively, facilitates and inhibits the ejaculatory behavior during the copulation testing 30 min. Bilateral microinjection of NMDA into PVN significantly increases the baseline LSNA, the peaking increment of LSNA occurred within 5 min from the time of NMDA microinjected into PVN [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02373124 | New York State Psychiatric Institute |
Cocaine Use Disorders
|
December 2014 | Phase 1|Phase 2 |
| NCT04244058 | Weill Medical College of Cornell University |
Disorder of Consciousness|Traumatic Brain Injury
|
September 23, 2020 | Early Phase 1 |
| NCT00163059 | Pfizer |
Depressive Disorder, Major
|
May 2004 | Phase 2 |
| NCT02950233 | Population Health Research Institute |
Pain, Postoperative
|
May 4, 2017 | Phase 3 |
| NCT02097706 | The Alfred |
Borderline Personality Disorder
|
January 2015 | Phase 2 |
| NCT00163085 | Pfizer |
Parkinson´s Disease
|
May 2005 | Phase 2 |
| NCT03414931 | Chang Gung Memorial Hospital |
Depressive Disorder, Major
|
January 2016 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
H 2 O : 33.33 mg/mL ( 226.53 mM ; Need ultrasonic)
DMSO : 10 mg/mL ( 67.97 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 6.7967 mL | 33.9836 mL | 67.9671 mL |
| 5 mM | 1.3593 mL | 6.7967 mL | 13.5934 mL |
| 10 mM | 0.6797 mL | 3.3984 mL | 6.7967 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 36.67 mg/mL (249.24 mM); Clear solution; Need ultrasonic
-
2.
-
3.
Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 1 mg/mL (6.80 mM); Clear solution
-
4.
Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: ≥ 1 mg/mL (6.80 mM); Clear solution
References
- [1] Xia JD, et al. Centrally mediated ejaculatory response via sympathetic outflow in rats: role of N-methyl-D-aspartic acid receptors in paraventricular nucleus. Andrology. 2016 Nov 16.
- [2] Yoneda Y, et al. Enhancement of [3H]glutamate binding by N-methyl-D-aspartic acid in rat adrenal. Brain Res. 1987 Mar 17;406(1-2):24-31.
- [3] Jiang L, et al. Decrease of growth and differentiation factor 10 contributes to neuropathic pain through N-methyl-D-aspartate receptor activation. Neuroreport. 2017 May 24;28(8):444-450.
Synonyms